Bicycle Therapeutics financials
$3.65−1.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $72.6M | $35.3M | $27.0M | $14.5M | $11.7M | $10.4M | $13.8M |
| Gross profit | $72.6M | $35.3M | $27.0M | $14.5M | $11.7M | $10.4M | $13.8M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$247.1M | -$209.9M | -$189.9M | -$116.7M | -$65.6M | -$52.0M | -$26.3M |
| Net income | -$219.0M | -$169.0M | -$180.7M | -$112.7M | -$66.8M | -$51.0M | -$30.6M |
| Net margin | −301.7% | −479.2% | −669.7% | −779.3% | −571.2% | −491.0% | −221.8% |
| Diluted EPS | $-3.16 | $-2.90 | $-5.08 | $-3.80 | $-2.67 | $-2.66 | $-2.77 |
| EBITDA | -$240.6M | -$202.7M | -$183.4M | -$113.0M | -$64.2M | -$50.7M | -$25.3M |
| Operating cash flow | -$249.7M | -$164.7M | -$60.6M | -$86.1M | -$14.8M | -$17.8M | -$28.6M |
| Free cash flow | -$252.0M | -$166.0M | -$63.6M | -$105.1M | -$16.8M | -$19.0M | -$30.2M |
| Diluted shares | 69.3M | 58.2M | 35.6M | 29.7M | 25.1M | 19.1M | 11.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $628.1M | $879.5M | $526.4M | $339.2M | $438.7M | $136.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $30.7M | $30.3M | $29.9M | $14.5M |
| Total assets | $717.6M | $956.9M | $595.3M | $410.6M | $479.8M | $161.2M |
| Total liabilities | $107.6M | $163.8M | $224.4M | $139.8M | $133.5M | $65.7M |
| Shareholders' equity | $610.0M | $793.1M | $370.9M | $270.8M | $346.3M | $95.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology